An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria (BEFLEX)

Pfizer

Status: Completed

Conditions: Plaque Psoriasis Patients

Treatments: Other: Enbrel treatment

Study type: Observational

Funder types: Industry

Identifiers

NCT01557283

BEFLEX

B1801314

Details and patient eligibility

About

With the new reimbursement criteria, we want:

To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year.

To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment

Full description

100 patients will be followed for at least 1 year

Enrollment: 140 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient restarts or is starting treatment with Enbrel for his/her psoriasis in alignment with reimbursement criteria
• Patients ≥18 year
• Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion criteria

N/A

Trial design

140 participants in 1 patient group

Plaque psoriasis patients

Description:

Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria

Treatment:

Other: Enbrel treatment